RxDoctor Payments Data

Priyanka Kanth

Gastroenterology · Salt Lake City, UTNPI 1679773469

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $500 of the $810 with a category attached, or 61.7%. Provepharm Inc. accounts for 61.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $500 and has fallen 83.3% since, to $83 in 2024. That places this record below the midpoint for gastroenterology clinicians in UT, where the typical reported total is $2,186.

$810in general payments, 2019–2025

Across 7 payments — averaging $115.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Provepharm Inc.$500
  • Boston Scientific$141
  • Promega Corporation$59
  • Celltrion USA Inc.$31
  • Janssen Scientific Affairs, LLC$27
  • Johnson & Johnson$26
  • plus $26 from 1 others
$1,324,353in research payments, 2019–2025

Across 49 payments — averaging $27,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$1.2M
  • Mallinckrodt Enterprises LLC$83K

What the payments were for

  • Consulting fees$50062%
  • Food & beverage$31038%

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$810 in reported general payments places this provider in the 35th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$50,085
Medicare patients
214
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$12,671
Omeprazole30$441

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →